DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Universitat Autònoma de Barcelona
Barcelona, EspañaPublications in collaboration with researchers from Universitat Autònoma de Barcelona (8)
2021
-
Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891
-
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
European urology oncology, Vol. 4, Núm. 3, pp. 456-463
2020
-
Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
European Urology
-
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees
European Urology, Vol. 77, Núm. 2, pp. 223-250
-
Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy
Cancers, Vol. 12, Núm. 7, pp. 1-13
2019
-
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
Annals of Oncology, Vol. 30, Núm. 11, pp. 1697-1727
2017
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681